The strongest version of this narrative highlights a genuine shift in allergy treatment from reactive to proactive, disease-modifying therapies, driven by scientific innovation and rising global allergy rates. The companies profiled represent a diverse range of approaches—from peptide-based immunotherapies to multispecific antibodies—each addressing unmet needs in allergy care. The inclusion of clinical trial data, regulatory milestones, and market projections lends credibility to the claim that...